newsfilter
← Latest News
PR Newswire·

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...